| Year |
Citation |
Score |
| 2013 |
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clinical Pharmacology and Therapeutics. 94: 158-66. PMID 23588312 DOI: 10.1038/Clpt.2013.69 |
0.57 |
|
| 2009 |
Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. Journal of Breath Research. 3: 047002. PMID 21386199 DOI: 10.1088/1752-7155/3/4/047002 |
0.545 |
|
| 2008 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 18: 25-35. PMID 18216719 DOI: 10.1097/Fpc.0B013E3282F2F134 |
0.626 |
|
| 2007 |
Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pakistan Journal of Medical Sciences. 23: 832-839. PMID 18846242 DOI: 10.1200/Jco.2006.24.18_Suppl.2056 |
0.635 |
|
| 2007 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 17: 973-87. PMID 18075467 DOI: 10.1097/Fpc.0B013E3282F01788 |
0.614 |
|
| 2007 |
Fourie J, Mattison LK, Wood TE, Posey JA, Modak A, Diasio RB. The 2-13C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-13C-uracil breath test (UraBT) Journal of Clinical Oncology. 25: 2551-2551. DOI: 10.1200/Jco.2007.25.18_Suppl.2551 |
0.586 |
|
| 2006 |
Saif MW, Hashmi S, Mattison L, Donovan WB, Diasio RB. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anti-Cancer Drugs. 17: 1095-8. PMID 17001184 DOI: 10.1097/01.Cad.0000231479.30524.0E |
0.537 |
|
| 2006 |
Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5491-5. PMID 17000684 DOI: 10.1158/1078-0432.Ccr-06-0747 |
0.614 |
|
| 2006 |
Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 549-55. PMID 16428499 DOI: 10.1158/1078-0432.Ccr-05-2020 |
0.596 |
|
| 2006 |
Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemotherapy and Pharmacology. 58: 396-401. PMID 16421754 DOI: 10.1007/S00280-005-0174-5 |
0.506 |
|
| 2006 |
Reed HA, Ezzeldin HH, Mattison LK, Diasio RB. Molecular basis of altered uracil catabolism in individuals with 5-FU toxicity and normal DPD enzyme activity Journal of Clinical Oncology. 24: 3070-3070. DOI: 10.1200/Jco.2006.24.18_Suppl.3070 |
0.641 |
|
| 2006 |
MATTISON L, ACOSTA E, FOURIE J, DIASIO R. LBOVI-B-2Describing the catabolism of orally administered 2-13C-uracil in normal and dihydropyrimidine dehydrogenase deficient subjects using a parent/metabolite/breath model Clinical Pharmacology & Therapeutics. 79: P83-P83. DOI: 10.1016/J.Clpt.2005.12.298 |
0.564 |
|
| 2005 |
Mattison LK, Fourie J, Carpenter M, Ezzeldin H, Johnson MR, Saif M, Modak A, Diasio RB. Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2004. PMID 27946814 DOI: 10.1200/Jco.2005.23.16_Suppl.2004 |
0.608 |
|
| 2005 |
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8699-705. PMID 16361556 DOI: 10.1158/1078-0432.Ccr-05-1520 |
0.6 |
|
| 2004 |
Mattison LK, Johnson MR, Saif W, Modak AS, Hirao Y, Koga T, Shimizu T, Diasio RB. Validation of a novel [2-(13)C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-(13)C]-uracil (URA) and [2-(13)C]-dihydrouracil (DHU) plasma levels. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2130. PMID 28016902 DOI: 10.1200/Jco.2004.22.14_Suppl.2130 |
0.591 |
|
| 2004 |
Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2652-8. PMID 15102667 DOI: 10.1158/1078-0432.Ccr-03-0374 |
0.622 |
|
| 2002 |
Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 3: 485-92. PMID 12164772 DOI: 10.1517/14622416.3.4.485 |
0.623 |
|
| 2002 |
Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 12: 133-44. PMID 11875367 DOI: 10.1097/00008571-200203000-00007 |
0.562 |
|
| Show low-probability matches. |